Last reviewed · How we verify
Aliskiren+HCTZ - Phase 2
Aliskiren blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin, while HCTZ reduces blood pressure through diuresis and vasodilation.
Aliskiren blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin, while HCTZ reduces blood pressure through diuresis and vasodilation. Used for Hypertension.
At a glance
| Generic name | Aliskiren+HCTZ - Phase 2 |
|---|---|
| Sponsor | Novartis |
| Drug class | Direct renin inhibitor + thiazide diuretic combination |
| Target | Renin; sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aliskiren is a direct renin inhibitor that prevents the conversion of angiotensinogen to angiotensin I, thereby suppressing the entire RAAS cascade. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that increases sodium and water excretion while causing mild vasodilation. The combination provides complementary antihypertensive effects targeting different pathways of blood pressure regulation.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (with aliskiren)
- Hypokalemia (with HCTZ)
- Headache
- Cough
Key clinical trials
- Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension (PHASE4)
- A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (PHASE4)
- Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension (PHASE4)
- Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (PHASE4)
- Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans (PHASE4)
- Aliskiren Study of Safety and Efficacy in Senior Hypertensives (PHASE4)
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension (PHASE4)
- Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren+HCTZ - Phase 2 CI brief — competitive landscape report
- Aliskiren+HCTZ - Phase 2 updates RSS · CI watch RSS
- Novartis portfolio CI